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Abstract In experimental autoimmune encephalomyelitis
(EAE), an animal model for multiple sclerosis (MS), loss
of the blood–brain barrier (BBB) tight junction (TJ) protein
claudin-3 correlates with immune cell inﬁltration into the
CNS and BBB leakiness. Here we show that sealing BBB
TJs by ectopic tetracycline-regulated expression of the TJ
protein claudin-1 in Tie-2 tTA//TRE-claudin-1 double
transgenic C57BL/6 mice had no inﬂuence on immune cell
trafﬁcking across the BBB during EAE and furthermore did
not inﬂuence the onset and severity of the ﬁrst clinical
disease episode. However, expression of claudin-1 did
signiﬁcantly reduce BBB leakiness for both blood borne
tracers and endogenous plasma proteins speciﬁcally around
vessels expressing claudin-1. In addition, mice expressing
claudin-1 exhibited a reduced disease burden during the
chronic phase of EAE as compared to control littermates.
Our study identiﬁes BBB TJs as the critical structure reg-
ulating BBB permeability but not immune cell trafﬁcking
into CNS during EAE, and indicates BBB dysfunction is a
potential key event contributing to disease burden in the
chronic phase of EAE. Our observations suggest that sta-
bilizing BBB barrier function by therapeutic targeting of
TJs may be beneﬁcial in treating MS, especially when anti-
inﬂammatory treatments have failed.
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Introduction
Under physiological conditions, the blood–brain barrier
(BBB) maintains homeostasis of the central nervous system
(CNS) by restricting uncontrolled diffusion of water solu-
ble molecules from the blood into the CNS and by limiting
immune cell trafﬁcking into the CNS. The BBB is estab-
lished at the level of CNS microvascular endothelial cells,
which are highly specialized to achieve precise control
over the substances that leave or enter the brain. Lack of
fenestrae and an extremely low pinocytotic activity of BBB
endothelial cells inhibit the transcellular passage of mole-
cules across the barrier whereas tight junctions (TJ)
between the brain endothelial cells restrict the paracellular
diffusion of solutes and ions across the BBB [47]. BBB TJs
are unique as in a belt-like region the opposing membranes
of adjacent brain endothelial cells form continuous and
highly interconnected TJ strands, which appear as a chain
of fusion points at the ultrastructural level [10]. In freeze-
fracture electron microscopy analysis the fusion points are
visualized as strands of TJ particles [46]. At the BBB TJ
particles are predominantly associated with the protoplas-
mic membrane leaﬂets (P-face) as usually observed in
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peripheral endothelial cells are rather found associated with
the extracellular fracture face (E-face) of the membrane
bilayer. TJ strands or particles are composed of integral
transmembrane proteins [16], of which occludin and the
claudins have been identiﬁed to date [40, 41]. Although
structurally unrelated, occludin and the claudins are both
type II transmembrane proteins bearing 4 transmembrane
domains. They are linked to the actin cytoskeleton by TJ
associated cytoplasmic peripheral membrane proteins of
the MAGUK (membrane associated with a guanylyl
kinase-like domain) family, such as zonula occludens
(ZO)-1, ZO-2 and ZO-3 [41, 45]. Occludin is highly
expressed in TJ of the BBB but not in endothelial TJs of
non-neuronal tissues [4, 22], while intact BBB TJs can
form in the absence of occludin in vivo [38]. In contrast to
occludin, claudins have been shown to be sufﬁcient to
induce TJ strands when transfected into ﬁbroblasts [15].
The claudin family is comprised of 24 members, which
form the backbone of TJs by establishing homophilic and
heterophilic interactions via their extracellular loops [26].
The individual claudins display tissue speciﬁc expression
patterns and differ in their individual properties in forming
dynamic aqueous pores that allow size- and charge-selec-
tive paracellular diffusion [17]. Within each tissue,
expression of a unique combination of claudins, therefore,
determines the respective paracellular tightness of the TJs
for different solutes. Claudin-5 has been demonstrated to
be the endothelial cell-speciﬁc component of TJs strands
[34] and is also expressed in BBB TJs [35]. Upon trans-
fection into ﬁbroblasts claudin-5 induces E-face associated
TJs [34], whereas claudin-3, which is speciﬁcally expres-
sed in TJ of CNS but not other endothelial cells [44, 47],
induces P-face associated TJs [16]. This suggests a speciﬁc
function for claudin-3 in BBB TJs, which is supported
further by the recent observation that expression of clau-
din-3 correlates with BBB maturation in response to Wnt/
b-catenin signaling during development [30]. Whereas the
exact function of claudin-3 in BBB TJs remains to be
investigated, an essential function for claudin-5 in sealing
BBB TJs against small molecules up to 800 Da has been
demonstrated by genetic deletion of claudin-5 in mice
[35]. In addition to claudin-5 and claudin-3, expression
of claudin-12 has also been described at the BBB [35].
Previous studies have shown immunostaining for clau-
din-1 in brain endothelium [31]. Later studies, however,
which speciﬁcally excluded cross-reactivity of anti-clau-
din-1 antibodies with claudin-3 failed to detect any
immunostaining for claudin-1 in CNS parenchymal
microvessels or in primary mouse or human brain
endothelial cells [2, 20, 43, 47]. Thus, the combined
homophilic and heterophilic interactions between clau-
din-3, claudin-5, and probably also claudin-12, at the
BBB seem to be responsible for the unique barrier
function of the BBB TJs [26].
During neurological disorders such as multiple sclerosis
(MS) or its animal correlate experimental autoimmune
encephalomyelitis (EAE), focal loss of BBB integrity is
observed. MS is an inﬂammatory demyelinating disease of
the CNS, in which a large number of inﬂammatory cells
gains access to the CNS parenchyma forming perivascular
inﬂammatory lesions. Lesion formation in MS is known to
be associated with focal BBB dysfunction as visualized by
gadolinium-enhanced magnetic resonance imaging and
occurs early in the pathogenesis of new lesions in MS [24].
Immunohistological analysis of post mortem brain samples
of MS patients has identiﬁed BBB TJs as the anatomical
route for BBB leakiness in MS [29]. In these studies,
abnormal distributions of TJ proteins such as occludin and
ZO-1 in brain vessels were found to correlate with
enhanced BBB leakiness for serum proteins [25, 37]. EAE
reliably models the inﬂammatory phase of MS and BBB
alterations observed in EAE resemble those observed in
MS [1]. We have previously observed the speciﬁc loss of
claudin-3 immunostaining from those brain microvessels
that were surrounded by inﬂammatory inﬁltrates [47],
suggesting a direct role for inﬂammatory cells in disrupting
BBB TJs. While much has been learned regarding the
sequential steps of immune cell rolling or capture, adhesion
and crawling on the BBB, the cellular pathways and the
molecular cues mediating immune cell diapedesis across
the BBB are only just being unraveled (summarized in
[6, 19]). BBB TJs could be disrupted by the immune cells
penetrating the BBB on a paracellular route through the
endothelial cell–cell contacts or alternatively, immune cells
might traverse the BBB on a transcellular route through the
brain endothelial cell itself and thus indirectly alter BBB
TJ architecture (summarized in [9]).
In the present study, we therefore aimed to delineate the
role of BBB TJs in immune cell inﬁltration and focal BBB
leakiness during EAE. Based on our previous observation
of the speciﬁc loss of claudin-3 from BBB TJs, we
hypothesized that in brain endothelial cells ectopic
expression of claudin-1, which like claudin-3 induces
P-face associated TJs upon transfection into ﬁbroblasts
[15], might seal BBB TJs and therefore reduce the para-
cellular component of immune cell diapedesis across the
BBB and/or inﬂammation-induced BBB leakiness. This
notion is supported by previous ﬁndings demonstrating that
claudin-1 seals TJs in skin epithelial and lung endothelial
cells [13, 14]. Furthermore, TJ strands induced by claudin-
3 associate with those induced by claudin-1 suggesting that
ectopic expression of claudin-1 in BBB TJs would pro-
ductively integrate into the BBB TJ strands [16]. We,
therefore, established transgenic mouse lines with tetracy-
cline (TET)-regulated endothelial cell-speciﬁc expression
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we observed TET-induced expression of claudin-1 in
30–50% of PECAM-1
? CNS microvessels. This partial
expression of claudin-1 in BBB TJs sufﬁced to lead to a
signiﬁcant amelioration of chronic but not acute EAE in
double transgenic Tie-2 tTA//TRE–claudin-1 C57BL/6
mice compared to single transgenic littermates.
Materials and methods
Transgene construction
Construction of the Tie-2 tTA vector and production of
transgenic mice was described elsewhere [5]. The murine
claudin-1 cDNA clone (genbank entry AI663222) was
requested from the German Resource Center for Genome
Research (RZPD) and sequenced to verify integrity of the
open reading frame. The claudin-1 inducible construct was
then created by ligating an XhoI/SacII fragment carrying
the tet-response element (TRE from pUHD10-3; H. Bujard,
Heidelberg), a SacII/BglI claudin-1 fragment, a BamHI/
XbaI fragment containing an IRES and the EGFP open
reading frame (from pIRES2-EGFP; Clontech, Palo Alto),
and an XbaI/XhoI fragment containing the bovine growth
hormone poly(A) signal into the XhoI site of pBluescript II.
TRE-claudin-1 transgenic mice were then produced by
pronuclear injection into fertilized mouse oocytes as
described previously [5]. Six TRE-Claudin-1 transgenic
founder animals were created from which ﬁve independent
transgenic lines could be raised.
Genotyping
Transgenic mice were genotyped by PCR. The primers
tTA-FW2 (GACGCCTTAGCCATTGAGATG) and tTA-
REV2 (CAGTAGTAGGTGTTTCCCTTTCTTC) amplify
a product of 550 bp in size from the DNA of Tie-2 tTA
transgenic mice.
PCR using the primers CMV-IE FW (CCATAGAA
GACACCGGGACC) and IRES REV2 (AAGCGGCTTCG
GCCAGTAAC) ampliﬁes a product of 700 bp in size from
the DNA of TRE-Claudin-1 transgenic mice.
Mice
C57BL/6 mice were obtained from Harlan (Horst, The
Netherlands). The Tie-2-tTA activator line #7770 was
described before [5]. Double transgenic mice capable of
TET-inducible expression of claudin-1 were obtained by
crossing Tie2 tTA activator transgenic C57BL/6 mice with
responder mice carrying a unidirectional construct for
claudin–1. The experiments shown in the present study
were performed with the TRE-claudin-1 mouse lines
#23949 and #23974 backcrossed to the C57BL/6 back-
ground for at least 7 generations before being used in the
experiments. Double transgenic (Tie-2 tTA//TRE–claudin-
1) mice were obtained by breeding Tie-2-tTA activator
with TRE-claudin-1 responder mice. Mice in matings were
fed with Doxycycline supplemented chow (100 mg/kg;
Provimi Kliba, Kaiseraugst, Switzerland) to suppress
expression of claudin-1 in double transgenic pups during
embryonic development and until weaning at postnatal day
21. Mice were housed in the animal facility of the Uni-
versity of Bern under speciﬁc pathogen free conditions in
individually ventilated cages. All animal procedures were
performed in accordance with the Swiss legislation on the
protection of animals and approved by the respective
government authorities.
Antibodies and reagents
The following primary antibodies were used at 10–20 lg/ml
or as supernatants from hybridomas: rat anti-mouse JAM-A
(BV11 and BV12, from E. Dejana, Milan, Italy), rat anti-
mouse PECAM-1 (Mec13.3, BD Pharmingen, Heidelberg,
Germany); rat anti-mouse CD45 (M1/9) and rat anti-human
CD44 (Hermes-1 = 9B5, used as isotype control) (both
from ATCC, Rockville, MA, USA), rabbit anti-mouse
Claudin-5 (from H. Wolburg/H. Kalbacher, Tu ¨bingen,
Germany). The following antibodies were obtained from
Zymed, San Francisco, USA via LuBioScience GmbH,
Lucerne, Switzerland: mouse anti-mouse Claudin-5 (35-
2500), rabbit anti-mouse Claudin-1 (51-9000), rabbit anti-
mouse Claudin-3 (34-1700), rabbit anti-mouse Claudin-5
(34-1600), rabbit anit-mouse Occludin (71-1500), rabbit
anti-mouse ZO-1 (61-7300), rabbit anti-mouse ZO-2 (71-
1400). Rabbit anti-human ﬁbronectin (A0245, cross-reacts
with mouse ﬁbronectin) and rabbit anti-von Willebrand
Factor were from DAKO Cytomation, Glostrup, Denmark.
The following secondary antibodies were used at
3–10 lg/ml: Alexa Fluor 488 goat anti-rat, Alexa Fluor 488
goat anti-rabbit (both from Molecular Probes via Invitrogen
via LuBioScience GmbH, Lucerne, Switzerland), Cyanine
Cy3 goat anti-rat, Cyanine Cy3 goat anti-rabbit, Cyanine
Cy3 donkey anti-mouse (all from Jackson Immunoresearch
via Milan Analytica AG, La Roche, Switzerland).
RNA isolation, cDNA synthesis, Gene chip array
and qPCR of puriﬁed parenchymal mouse brain
capillaries
Isolation of PECAM-1
? parenchymal mouse brain capil-
laries from 4-week-old female C57BL/6 mice (Harlan,
Horst, The Netherlands) and RNA isolation from these
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microarray analysis (Mouse Genome 430 2.0 Array,
AffymetrixUK,HighWycombe,UK)wasperformedexactly
as described before [32]. qPCR was based on SYBR green
(MasterMix Plus for SYBR Assay I Low ROX, Eurogentec,
Seraing,Belgium)andcarriedoutonanAppliedBiosystems
7500 Real-Time PCR system (Applied Biosystems, War-
rington, UK). To compare expression levels of claudin-1
with claudin-5, detection of the endogenous reference probe
targeting the cDNA for s16 ribosomal protein was included
in each experiment (5 experiments total) and set to 1.0
according to the comparative comparative DCT method
(relative expression = 2DCT, DCT value = average CT
value of target-average CTvalue of endogenous reference).
Thefollowingprimerpairswereused:s16ribosomalprotein
(Rps16, NM_013647): forward primer GATATTCGGG
TCCGTGTGA, reverse primer TTGAGATGGACTGTCG
GATG, length of PCR product 69 bp; claudin-5
(NM_013805): forward primer ACGGGAGGAGCGCTTT
AC, reverse primer GTTGGCGAACCAGCAGAG, length
of PCR product: 65 bp; claudin-1 (NM_016674): forward
primer ACTCCTTGCTGAATCTGAACAGT, reverse pri-
mer GGACACAAAGATTGCGATCAG, length of PCR
product: 91 bp.
Immunoﬂuorescence stainings
Mice were anesthetized with Isoﬂuorane (Baxter, Arovet
AG, Zollikon, Switzerland) and perfused with cold phos-
phate buffered saline (PBS) through the left ventricle of the
heart. Brains were removed, coronally cut into three pieces,
embeddedinTissue-Tek(OCTcompound,SysmexDigitana
AG, Horgen Switzerland) and snap frozen in an isopentane
bath (2-Methylbutane, Grogg Chemie AG, Stettlen/Deiss-
wil, Switzerland) at -80C. Cryostat sections (6 lm) were
air dried overnight before staining. Sections were ﬁxed for
10 min with ethanol at 4C, followed by 1 min in acetone at
room temperature and rehydrated with Tris buffered saline
(TBS). Sections were blocked with blocking solution con-
taining 5% (w/v) skimmed milk, 0.3% (v/v) Triton X-100
(Fluka via Grogg Chemie AG, Stettlen/Deisswil, Switzer-
land) and 0.04% (w/v) NaN3 in TBS for 20 min. Primary
antibodies were incubated in the same buffer, unless they
were used as supernatants from hybridomas, for 1 h at room
temperature. Following the washes with TBS, sections were
incubated with secondary antibodies diluted in blocking
solutionfor1 hatroomtemperature.Sectionsweremounted
in Mowiol (Calbiochem via Grogg Chemie AG, Stettlen/
Deisswil, Switzerland). Sections were analyzed using a
Nikon Eclipse E600 microscope connected to a Nikon Dig-
italCameraDXM1200FwiththeNikonACT-1Version2.63
software (Nikon, Egg/ZH, Switzerland).
Induction of EAE in C57BL/6 mice
Active EAE was induced exactly as described before [8]b y
subcutaneous injection of 200 lg of myelin oligodendro-
cyte glycoprotein peptide (MOGaa35–55) emulsiﬁed in
complete Freund’s adjuvant (incomplete Freund’s adjuvant
(Santa Cruz, Switzerland) supplemented with 4 mg/ml
attenuated Mycobacterium tuberculosis (H37 RA, DIFCO
Laboratories, Detroit, MI) into 8-to 12-week-old female
C57BL/6 wild-type, single, and double transgenic Tie-2
tTA//TRE–claudin-1 mice. 300 ng pertussis toxin from
Bordetella pertussis (LuBioScience GmbH, Switzerland)
per mouse was administered intraperitoneally at days 1 and
3 post-immunization (p.i.). Assessment of clinical disease
activity was performed as described with the following
disease scores: 0 = healthy, 0.5 = limp tail, 1 = hind leg
paraparesis, 2 = hind leg paraplegia, and 3 = hind leg
paraplegia with incontinence [8]. A total of 6 EAE
experiments were performed comparing double and single
transgenic mice of the Tie-2 tTA//TRE–claudin-1 lines
23949 and 23974. Graph Pad Prism 4.0 software was used
to calculate area under the curve (AUC) values of EAE
clinical scores and for subsequent statistical analysis uti-
lizing Mann–Whitney test (non-parametric, unpaired).
In vivo BBB permeability assays
BBB leakiness for the small molecular tracert Hoechst
nuclear stain (HOE 33258, 534D, Calbiochem-Novabio-
chem, Laufelﬁngen, Switzerland) and for endogenous
ﬁbronectin was assessed in single and double transgenic
Tie-2 tTA//TRE–claudin-1 mice of lines 23949 and 23974
at day 50 post EAE induction. 100 ll of 2% Hoechst
nuclear stain in PBS was injected intravenously into each
mouse. 30 min after dye circulation, mice were decapi-
tated, brains were removed, coronally cut into three pieces,
which were embedded side by side in Tissue-Tek (OCT
compound, Sysmex Digitana AG, Horgen Switzerland) and
snap frozen in an isopentane bath (2-Methylbutane, Grogg
Chemie AG, Stettlen/Deisswil, Switzerland) at -80C.
Brain cryosections of 4 double and 6 single transgenic mice
were immunoﬂuorescently labeled for CD45 and claudin-1.
From each brain at least 10 cryosections (each showing 3
brain sections) were analyzed, with at least 70 lm between
individual sections analyzed. Inﬂammatory cuffs in the
brain parenchyma were identiﬁed by perivascular accu-
mulation of CD45
pos cells and subdivided into 4 leakiness
groups according to claudin-1 expression and Hoechst
leakage: claudin-1
pos/Hoechst
pos, claudin-1
pos/Hoechst
neg,
claudin-1
neg/Hoechst
pos and claudin-1
neg/Hoechst
neg. The
number of inﬂammatory cuffs was expressed either in
percentage per brain or as a ratio of Hoechst
pos to
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neg cuffs and statistically analyzed with unpaired t
test (Graph Pad Prism 4.0).
For quantiﬁcation of endogenous ﬁbronectin (FN) leak-
age across the BBB brain cryosections were performed as
described above on day 50 p.i. of 6 double and 9 single
transgenicTie-2tTA//TRE–claudin-1mice(lines23949and
23974). Pairs of serial sections were immunoﬂuorescently
double-stained for CD45/claudin-1 and CD45/ﬁbronectin,
respectively. Per individual brain section-pairs were ana-
lyzed withat least 70 lm between them. Inﬂammatory cuffs
in the brain parenchyma were identiﬁed by perivascular
accumulation of CD45
pos cells and subdivided into 4 ﬁbro-
nectin leakiness groups according to claudin-1 expression
andﬁbronectinleakage:claudin-1
pos/ﬁbronectin
pos,claudin-
1
pos/ﬁbronectin
neg, claudin-1
neg/ﬁbronectin
pos or claudin-
1
neg/ﬁbronectin
neg. The number of inﬂammatory cuffs was
expressed either in percentage per brain or as a ratio of
ﬁbronectin
pos to ﬁbronectin
neg cuffs and statistically ana-
lyzed with unpaired t test (Graph Pad Prism 4.0).
Quantiﬁcation of inﬂammatory cuffs
The number of CD45
pos inﬂammatory cellular inﬁltrates
surrounding CNS blood vessels (‘‘inﬂammatory cuffs’’)
was counted in a total of 10 double transgenic and 15 single
transgenic Tie-2 tTA//TRE–claudin-1 mice from lines
23949 and 23974 at day 50 post-immunization and were
classiﬁed based on their localization as leptomeningeal
cuffs surrounding meningeal vessels, as periventricular
when localized in direct vicinity to the CNS ventricles and
as parenchymal cuffs when surrounding parenchymal
blood vessels. The analysis was restricted to the brain as
merging of parenchymal and meningeal inﬂammatory
inﬁltrates in the spinal cord prohibited quantitation of
individual inﬂammatory cuffs in spatial relation to indi-
vidual blood vessels. The number of inﬂammatory cuffs
per mouse was calculated as mean number of inﬂammatory
cuffs per brain section and median number of inﬂammatory
cuffs for all mice was statistically analyzed using the
Mann–Whitney U test (Graph Pad Prism 4.0).
MOG speciﬁc T cell priming
In vitro antigen-recall assays were carried out with
MOGaa35–55-immunized single, and double transgenic Tie-
2 tTA//TRE–claudin-1 mice, as described before [42]. At
day 10 post-immunization, mice were killed and draining
lymph nodes were dissected. Single-cell suspensions were
produced and cells were seeded in 96-well plates at
2 9 10
5 cells/well in RPMI 1640 supplemented with 10%
FBS (GIBCO, LuBiosience, Lucerne, Switzerland), 10
U/mL penicillin/streptomycin, 2 mM L-glutamine, 1%
nonessential amino acids, 1 mM sodium pyruvate and
0.05 mM b-mercaptoethanol (Grogg Chemie AG).
Increasing concentrations of MOGaa35–55 were used to test
for antigen-speciﬁc T cell proliferation. T cell proliferation
induced by cross-linking of CD3 and CD28 with 0.1 lg/ml
of the respective antibodies (clones 145-2C11 and 37.51,
Pharmingen BD Biosciences, Switzerland) was used as a
positive control. T cell proliferation in medium without
antigen or with 10 lg/ml of puriﬁed protein derivate of
Mycobacterium tuberculosis (PPD, CFA-component) was
used as negative and adjuvants control, respectively. All
samples were plated in triplicates. [
3H]Thymidine
(1 lCi/mL) was added 16 h prior to harvesting the cultures
on glass ﬁber ﬁlters using a cell harvester (Inotech, Dotti-
kon, Switzerland) and incorporation of [
3H]thymidine was
measured by liquid scintillation counting.
Statistics
Statistical analysis was performed with Graph Pad Prism
4.0, as described in the corresponding paragraphs.
Results
Expression of tight junction molecules in CNS
microvessels in C57BL/6 mice
Descriptions on the presence or absence of claudin-1 in
tight junctions (TJs) of blood vessels of the brain have been
controversial. To clarify the molecular architecture of brain
endothelial TJs and claudin-1 expression in the brain we
have, therefore, performed a thorough immunoﬂuorescence
analysis for TJ and TJ associated proteins in frozen brain
sections of wild-type C57BL/6 mice differentiating
between their expression in brain parenchymal blood ves-
sels, meningeal blood vessels, the fenestrated choroid
plexus endothelium, the blood-cerebrospinal ﬂuid barrier
forming choroid plexus epithelium and ependymal cells
lining the ventricles (Table 1). As previously shown [47]
we detected occludin, ZO-1 and ZO-2, claudin-3 and
claudin-5 but not claudin-1 localized to TJs of parenchymal
and meningeal blood vessel endothelial cells. Interestingly,
diffuse claudin-1 immunostaining was observed in men-
ingeal blood vessel endothelial cells (Table 1; Fig. 2).
Endothelial cells from choroid plexus fenestrated micro-
vessels lacked occludin, claudin-1 and claudin-3, but
stained positive for claudin-5. Conﬁrming our previous
observations [48] TJs of the choroid plexus epithelium
expressed all molecules analyzed (including claudin-1 and
claudin-2) except claudin-5. Similarly, although ependy-
mal cells lining the ventricles do not form a tight barrier,
they stained positive for all TJ molecules analyzed with the
exception of claudin-5.
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mouse brain endothelial cells, we analyzed claudin-1
mRNA expression from freshly isolated PECAM-1
pos brain
parenchymal microvascular fragments by microarray and
quantitative RT-PCR. Both analyses conﬁrmed claudin-5
and the absence of claudin-1 mRNA expression in brain
endothelial cells (Fig. 1;[ 32]. Microarray data (CEL, CHP,
and RMA ﬁles) are available at GEO (accession number
GSE14375).
Establishment and characterization of Tie2-tTA//TRE-
claudin-1 double transgenic mice
To determine the inﬂuence of TJ integrity on immune
cell recruitment across the BBB and BBB leakiness
during EAE we established transgenic mice with endo-
thelial cell-speciﬁc and TET-inducible expression of
claudin-1 using the TET-OFF system [5]. Inducibility of
claudin-1 expression in responder lines was tested by
mating TRE-claudin-1 mice with Tie-2 tTA activator
mice expressing tTA in an endothelial cell-speciﬁc
manner to generate double transgenic mice [5]. Five
TRE-claudin-1 responder mice lines were characterized
for expression of claudin-1 and GFP (11 mice for line
23949, 12 mice for line 23954, 10 mice for line 23970,
19 mice for line 23971 and 8 mice for line 23974).
Whereas expression of GFP was only detected in line
23974, TET-induced expression of claudin-1 was
observed in all ﬁve lines. However, only *30% of
PECAM-1
? parenchymal vessels displayed positive
staining for TET-regulated claudin-1 correctly localized
to the cell-to-cell junctions (e.g. 61 claudin-1
?PECAM-
1
? from 182 PECAM-1
? brain microvessels in line
23949 and 70 claudin-1
?PECAM-1
? from 211 PECAM-
1
? brain microvessles in line 23974; Fig. 2). TRE-clau-
din-1 responder lines #23949 and #23974 revealed the
highest endothelial expression of claudin-1 and were
chosen for further analysis. Wild-type C57BL/6 mice
(Table 1) and single transgenic mice (Fig. 2) did not
show positive staining for claudin-1 in brain parenchy-
mal vessels, although we detected endogenous junctional
claudin-1 staining in the epithelial cells of the choroid
plexus and diffuse rather than junctional claudin-1
staining in endothelial cells of meningeal vessels.
Double transgenic Tie-2 tTA//TRE-claudin-1 C57BL/6
mice did not show any apparent phenotypic differences in
the overall anatomy of their organs when compared to
single transgenic and wild-type littermates. Histological
analysis of PECAM-1
? blood vessels in tissue sections of
the brain, spinal cord and the secondary lymphoid organs
of double transgenic Tie-2 tTA//TRE-claudin-1 C57BL/6
mice revealed no obvious differences in the vascular
architecture of these organs compared to the organs in
single transgenic or wild-type littermates. Moreover, size
and cellular composition of the secondary lymphoid organs
was not altered in double transgenic Tie-2 tTA//TRE-
claudin-1 C57BL/6 mice compared to single transgenic and
wild-type littermates as determined by FACS analysis (data
not shown). Interestingly, TET-induced claudin-1 was not
expressed in high endothelial venules of double transgenic
Tie-2 tTA//TRE-claudin-1 C57BL/6 mice and would,
therefore, not interfere with lymphocyte recirculation to
lymph nodes.
Table 1 Detection of tight
junction proteins by
immunoﬂuorescence staining of
the healthy brain
a Diffuse rather than junctional
staining
Parenchymal blood
vessel endothelium
Meningeal blood
vessel endothelium
Choroid plexus
endothelium
Choroid plexus
epithelium
Ependymal
cells
Claudin-1 – ?
a – ??
Claudin-2 – – – ??
Claudin-3 ??– ?±
Claudin-5 ??? ––
Occludin ??– ??
ZO-1 ? ? ???
ZO-2 ? ? ???
Fig. 1 Claudin-1 is not expressed in parenchymal CNS microvessels.
mRNA expression level of Claudin-1 and Claudin-5 in parenchymal
CNS microvascular endothelial cells was tested by quantitative RT-
PCR with the s16 ribosomal protein (Rps16) set to 1.0. As a source
for RNA mouse brain microvessels were used immediately after their
isolation. Data express mean values of 5 qPCRs carried out in
triplicates ± standard error. b.d. below limit of detection
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123Fig. 2 Expression of claudin-1
in the brains of Tie-2 tTA//TRE-
claudin-1 double and single
transgenic mice.
Immunoﬂuorescence staining
for claudin-1
? (red) and
PECAM-1
? (green) in frozen
brain sections of double
transgenic Tie-2 tTA//TRE–
claudin-1 mice and single
transgenic littermates from line
23949 is shown. Expression of
claudin-1 was detected in
PECAM-1 ? parenchymal
blood vessels in the brain of
Tie-2 tTA//TRE-claudin-1
double transgenic mice but not
in single transgenic littermates.
In addition, diffuse claudin-1
immunostaining was detected in
PECAM-1
? vascular
endothelial cells within the
leptomeninges and in cell-
junctions of choroid plexus
epithelial cells in Tie-2 tTA//
TRE-claudin-1 double
transgenic and single transgenic
mice. Scale bar 20 lm
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123Ectopic TET-regulated claudin-1 ameliorates chronic
but not acute experimental autoimmune
encephalomyelitis (EAE)
We next asked, if TET-regulated claudin-1, despite limited
expression levels in PECAM-1
? brain microvessels, seals
BBB TJs or impacts pathogenesis of MOGaa35–55-induced
EAE. We, therefore, compared EAE development in double
transgenic Tie-2 tTA//TRE-claudin-1 C57BL/6 mice versus
in single transgenic Tie-1tTA or TRE-claudin-1 littermates
(lines #23949 and #23974, respectively). In addition, in the
ﬁrst 3 experiments wild-type C57BL/6 littermates were
included to test for changes in EAE pathogenesis in single
transgenicC57BL/6mice(datanotshown).Nodifferencein
the day of onset of clinical EAE nor the maximum clinical
score was observed between Tie-2 tTA//TRE-claudin-1
C57BL/6 mice, and single transgenic or wild-type litter-
mates (Fig. 3 and data not shown). In contrast, starting from
day 30 p.i., we observed a signiﬁcantly milder disease score
forTie-2tTA//TRE-claudin-1C57BL/6miceascomparedto
single transgenic or wild-type littermates (Fig. 3a and data
notshown),resulting inoverallmilderchronic EAE inTie-2
tTA//TRE-claudin-1 C57BL/6 mice (Fig. 3b). Combined
with our observation that MOG-speciﬁc T cell priming was
unaltered in Tie-2 tTA//TRE-claudin-1 C57BL/6 mice
compared to single transgenic littermates (data not shown),
the data suggest that TET-regulated claudin-1 expression
ameliorates chronic but not acute EAE.
TET-regulated claudin-1 does not inﬂuence immune
cell inﬁltration into the CNS during EAE
To determine if TET-regulated claudin-1 reduces
immune cell inﬁltration across the BBB, we quantiﬁed
CD45
? inﬂammatory inﬁltrates surrounding PECAM-1
?
microvessels (inﬂammatory cuffs) in brain sections at
day 50 after induction of EAE. Based on brain locali-
zation we categorized inﬂammatory cuffs in 3 groups:
(1) meningeal cuffs localized around leptomeningeal
vessels, (2) periventricular cuffs localized directly adja-
cent to a ventricle, and (3) parenchymal cuffs localized
around parenchymal brain microvessels. We detected no
difference in the overall number of inﬂammatory cuffs
present in the brains of Tie-2//TRE-claudin-1 C57BL/6
double transgenic mice versus single transgenic litter-
mates nor in the number or ratio of inﬂammatory cuffs
in meningeal, periventricular and parenchymal compart-
ments (Fig. 4). Thus, TET-regulated claudin-1 did not
inﬂuence immune cell recruitment across the BBB during
EAE. An additional analysis counting 549 and 353
parenchymal cuffs in the brains of two Tie-2//TRE-
claudin-1 C57BL/6 double transgenic mice and 2 single
transgenic littermates, respectively, during the ﬁrst clin-
ical episode of EAE (day 18 p.i., clinical score 1) further
supports the notion that TET-regulated claudin-1 did not
interfere with the migration of immune cells across the
BBB during EAE.
Fig. 3 TET-regulated claudin-1 ameliorates chronic EAE Active
EAE was induced in Tie2-tTA//TRE-claudin-1 double transgenic
mice and single transgenic littermates from lines 23949 and 23974,
respectively, by subcutaneous immunization with MOGaa35–55 in
CFA. a Data show mean disease scores of 4 animals per group ±
SEM, evaluated daily following induction of EAE. Black line with
open squares indicate single transgenic mice line 23974; dark line
with ﬁlled squares indicate double transgenic mice line 23974; gray
line with open circles indicate single transgenic mice line 23949; light
gray line with ﬁlled circles indicate double transgenic mice line
23949. One representative experiment out of six comparing a total of
20 Tie2-tTA//TRE-claudin-1 double transgenic mice with 19 single
transgenic mice from line 23974 and 31 double transgenic mice with
33 single transgenic mice from line 23949 is shown. b The area under
the curve (AUC) was calculated from the EAE clinical course of each
mouse between day 30 and day 50 post-immunization. Shown are the
mean AUC values for each group ± SEM. Statistical analysis of
AUC values with the Mann–Whitney test revealed signiﬁcantly
reduced EAE severity in double transgenic (ﬁlled bars) compared to
single transgenic (open bars) mice in both TRE-claudin-1 lines.
*P\0.05; **P\0.005
608 Acta Neuropathol (2011) 122:601–614
123TET-regulated claudin-1 reduces BBB permeability
in chronic EAE
To investigate, if amelioration of chronic EAE in Tie-2
tTA//TRE-claudin-1 C57BL/6 mice correlated with
reduced BBB leakiness, in vivo BBB permeability was
examined using intravenous injection of Hoechst nuclear
dye, which measures BBB permeability at a particular time
point and with high sensitivity due to its small size of
540 Da. Further, staining for endogenous plasma ﬁbro-
nectin, which accumulates in the brain parenchyma over
time during EAE, allows a retrospective view of BBB
leakage.
Hoechst dye was injected intravenously into Tie-2 tTA//
TRE-claudin-1 C57BL/6 mice and single transgenic lit-
termates at day 50 after induction of EAE, after 30 min of
dye circulation, brains were removed, and immunoﬂuor-
escently stained for claudin-1 and for inﬁltrating
leukocytes with the pan-leukocyte marker CD45. In both
Tie-2 tTA//TRE-claudin-1 C57BL/6 mice and single
transgenic littermates Hoechst dye leakage was restricted
to vessels with concurrent perivascular accumulation of
CD45
? leukocytes.
Since Hoechst dye leakage was observed in all
inﬂammatory cuffs surrounding meningeal brain and peri-
ventricular microvessels, further quantitative analysis was
restricted to parenchymal inﬂammatory cuffs. In Tie-2
tTA//TRE-claudin-1 C57BL/6 mice as compared to single
transgenic littermates, a signiﬁcantly increased percentage
of parenchymal inﬂammatory cuffs around brain micro-
vessels were impermeable to Hoechst dye (Fig. 5a). These
data suggest amelioration of chronic EAE as observed in
Tie-2 tTA//TRE-claudin-1 C57BL/6 mice may be a con-
sequence of claudin-1 mediated tightening of BBB TJs
leading to reduced BBB permeability during chronic EAE.
Therefore, for each microvessel TET-regulated claudin-1
expression was correlated with BBB leakiness to Hoechst
dye. Parenchymal inﬂammatory cuffs were categorized in 4
groups by junctional claudin-1 expression and Hoechst
leakage as follows: (1) claudin-1
pos/Hoechst
pos, (2) clau-
din-1
pos/Hoechst
neg, (3) claudin-1
neg/Hoechst
pos, and (4)
claudin-1
neg/Hoechst
neg. All 4 categories of inﬂammatory
cuffs were observed in Tie-2 tTA//TRE-claudin-1 C57BL/6
mice, whereas only claudin-1
neg/Hoechst
pos and claudin-
1
neg/Hoechst
neg inﬂammatory cuffs were present in single
transgenic littermates (Fig. 5b). As expected, no signiﬁcant
difference in Hoechst
neg/Hoechst
pos ratios in claudin-1
neg
inﬂammatory cuffs in Tie-2 tTA//TRE-claudin-1 C57BL/6
mice versus single transgenic littermates was found
(Fig. 5c). In contrast, Hoechst
neg/Hoechst
pos ratios of
inﬂammatory cuffs around claudin-1
pos versus claudin-1
neg
microvessels revealed a signiﬁcant increase supporting the
conclusion that TET-regulated claudin-1 increases TJ
integrity and reduces BBB leakiness for Hoechst dye in
chronic EAE.
To extend these observations, we additionally assessed
BBB permeability by staining for the endogenous plasma
marker ﬁbronectin, which is found to accumulate around
leaky brain microvessels during EAE. Consistent with
Hoechst dye data Tie-2 tTA//TRE-claudin-1 C57BL/6
mice displayed a signiﬁcantly increased number of ﬁbro-
nectin-impermeable inﬂammatory cuffs versus single
transgenic littermates (Fig. 6a). Parenchymal inﬂammatory
cuffs were again subdivided into 4 groups based on
expression of endothelial expression of claudin-1 and
presence of perivascular ﬁbronectin, with claudin-1
neg/
ﬁbronectin
neg and claudin-1
neg/ﬁbronectin
pos inﬂammatory
cuffs present in both double and single transgenic mice and
claudin-1
pos/ﬁbronectin
neg and claudin-1
pos/ﬁbronectin
pos
inﬂammatory cuffs found only in double transgenic mice
(Fig. 6b). Based on these groups, we quantiﬁed the
inﬂammatory cuffs and calculated the ratio of ﬁbronec-
tin
neg/ﬁbronectin
pos parenchymal cuffs versus claudin-1
expression as a parameter of BBB tightness (Fig. 6c).
Again as expected, no signiﬁcant difference in ﬁbronec-
tin
neg/ﬁbronectin
pos ratios of claudin-1
neg inﬂammatory
cuffs was observed in Tie-2 tTA//TRE-claudin-1 C57BL/6
mice versus single transgenic littermates (Fig. 6c). In
contrast, ﬁbronectin
neg/ﬁbronectin
pos ratios for claudin-1
pos
inﬂammatory cuffs versus claudin-1
neg inﬂammatory cuffs
revealed a signiﬁcant increase supporting the conclusion
Fig. 4 TET-regulated claudin-1 does not inﬂuence the number of
inﬂammatory cuffs in the brain. Inﬂammatory cuffs were counted in a
total of 10 double transgenic (dtg) and 15 single transgenic (stg) Tie2-
tTA//TRE-claudin-1 mice of lines 23974 and 23949 in 168 versus 147
brain sections, respectively. A total of 1020 versus 1338 parenchymal
cuffs (P), 474 versus 510 leptomeningeal cuffs (M) and 197 versus
170 periventricular cuffs (V) in double transgenic versus single
transgenic mice, respectively, are included into the analysis. Each dot
represents the mean number of inﬂammatory cuffs/per brain section
of one mouse. Horizontal lines depict median for each group. Mann–
Whitney U analysis revealed no signiﬁcant differences comparing the
number of cuffs in stg versus dtg mice
Acta Neuropathol (2011) 122:601–614 609
123Fig. 5 TET-regulated claudin-1 induces BBB tightening for Hoechst
dye in chronic EAE. At the end of an EAE experiment (day 50 p.i.),
Hoechst dye was injected intravenously into 6 single and 4 double
transgenic Tie2-tTA//TRE-claudin-1 mice. Brain cryosections of
these mice were stained for Claudin-1 (red) and CD45 (green).
Leakage of the nuclear dye Hoechst can be observed in blue. a The
mean percentage (±SD) of inﬂammatory cuffs per brain localized
around Hoechst-impermeable BBB vessels is signiﬁcantly increased
in double transgenic compared to single transgenic mice. b The
following parenchymal cuffs are shown: inﬂammatory cuffs in single
and double transgenic mice that localized around BBB vessels that do
not stain positive for TET-regulated laudin-1 and are either permeable
for Hoechst dye or not; and inﬂammatory cuffs in double transgenic
mice localized around claudin-1-expressing BBB vessels which are
either permeable for Hoechst dye or not. Scale bar 20 lm. c The
mean ratio (±SD) of Hoechst-impermeable to Hoechst-permeable
inﬂammatory cuffs localized around claudin-1 negative vessels (in
single and double transgenic mice) or claudin-1 positive vessels (in
double transgenic mice) demonstrates highly signiﬁcant tightening of
the BBB for Hoechst dye in the presence of TET-regulated claudin-1.
*P\0.05; ***P\0.001
Fig. 6 TET-regulated claudin-1 induces BBB tightening for endog-
enous ﬁbronectin in EAE. Brains of 9 single and 6 double transgenic
TET-claudin-1 mice at day 50 post induction of aEAE were prepared,
cryo-sectioned and stained for CD45 (green) and claudin-1 (red)a s
well as for CD45 (green) and ﬁbronectin (red) on consecutive
sections. a The mean percentage (±SD) of inﬂammatory cuffs per
brain that have formed around ﬁbronectin-impermeable BBB vessels
is signiﬁcantly increased in double transgenic compared to single
transgenic mice. b Shown are representative parenchymal cuffs in a
double transgenic mouse. One has formed around a claudin-1
neg BBB
vessel and is leaky for plasma ﬁbronectin (upper row), one stains
positive for claudin-1 and is impermeable for plasma ﬁbronectin
(lower row). Note that ﬁbronectin-labeling also stains the basement
membranes of BBB vessels. Scale bar 50 lm. c The mean ratio
(±SD) of ﬁbronectin-impermeable to ﬁbronectin-permeable inﬂam-
matory cuffs that formed around claudin-1
neg vessels (in single and
double transgenic mice) or claudin-1
pos vessels (in double transgenic
mice) demonstrates highly signiﬁcant tightening of the BBB for
plasma ﬁbronectin in the presence of transgenic claudin-1. *P\0.05;
**P\0.005; ***P\0.001
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increases TJ integrity thereby reducing BBB leakiness to
ﬁbronectin. Determining the ratio of ﬁbronectin
neg/ﬁbro-
nectin
pos parenchymal cuffs versus claudin-1 expression in
mice during the ﬁrst clinical episode of EAE (day 18 p.i.)
conﬁrmed this ﬁnding. Taken together, our data demon-
strate that TET-regulated claudin-1 expression reduces
leakiness of brain microvessels surrounded by inﬂamma-
tory cells to exogenous tracers and endogenous plasma
proteins during EAE.
Discussion
Increased BBB permeability is a characteristic hallmark of
the pathological alterations observed in the CNS in MS and
in its animal model EAE [27]. In fact, breakdown of the
BBB identiﬁed by gadolinium-enhanced magnetic reso-
nance imaging is the earliest detectable event in the
development of most new CNS lesions in MS and is known
to be associated with inﬂammation [24, 28]. Amelioration
of clinical symptoms is observed, when CNS inﬂammation
resolves and BBB function is restored, supporting the
notion that lesion formation in MS is driven by inﬂam-
matory processes [28] and suggesting a causal relationship
between inﬂammatory cell recruitment into the CNS and
BBB dysfunction. Similarly, in EAE, loss of BBB integrity
has been recognized as a fundamental event in pathogen-
esis and further the magnitude of BBB dysfunction has
been correlated with disease severity [11]. The close
association of inﬂammation-induced BBB dysfunction with
immune cell entry into the CNS has, however, hampered
attempts to elucidate the speciﬁc contribution of BBB
dysfunction to MS pathogenesis.
Our present study provides evidence for the speciﬁc
contribution of focal BBB leakiness to disease pathogenesis
in EAE and identiﬁes the BBB TJs as potentially critical
structures for the observed BBB dysfunction during EAE.
Speciﬁcally, sealing BBB TJs by ectopic expression of
claudin-1 in Tie-2 tTA//TRE-claudin-1 double transgenic
C57BL/6 mice had no inﬂuence on immune cell trafﬁcking
across the BBB during EAE and therefore did not inﬂuence
theonsetnortheseverity oftheﬁrstclinicalepisode ofEAE.
However, expression of TET-regulated claudin-1 signiﬁ-
cantly reduced BBB leakiness for blood borne tracers or
endogenous plasma proteins speciﬁcally in claudin-1
expressing vessels. Further, a reduced disease burden in the
chronic phase of EAE was observed in Tie-2 tTA//TRE-
claudin-1 mice compared to control littermates. Our study,
which dissociates BBB leakiness from immune cell traf-
ﬁcking into the CNS during EAE, identiﬁes the BBB TJs as
critical structures regulating BBB permeability, and deﬁnes
BBB dysfunction as a potentially crucial underlying event
contributing to the disease burden in the chronic phase of
MS.
Previous studies on post mortem MS brains have already
suggested a relationship of BBB TJ abnormalities with BBB
hyperpermeability in MS. In these studies, evaluation of a
large number of brain vessels by immunoﬂuorescence
staining and semi-quantitative thick-section confocal anal-
ysis demonstrated TJ abnormalities manifested by beading,
interruption or absence of junctional immunostaining or
appearance of diffuse cytoplasmic staining for the TJ pro-
teins ZO-1, occludin and junctional adhesion molecule-A
(JAM-A)inupto40%ofthebloodvesselsinMSbraintissue
fromprimaryprogressiveandsecondaryprogressivedisease
states [25, 29, 36, 37]. Aberrant TJ morphology observed in
MS brains correlated with enhanced BBB leakiness for
serum proteins, highlighting that BBB TJ disruption under-
lies BBB leakiness in MS [25, 37]. Based on these
observations, these authors have proposed to consider BBB
TJ pathology—besides inﬂammation and demyelination—a
distinct entity of tissue injury in MS [37].
EAEreliablymodelstheinﬂammatoryphase ofMSanda
number of observations support the view that EAE equally
wellallowstomodeltheBBBTJpathologyobservedinMS.
Mirroring the observations made in MS tissue samples,
disrupted immunostaining for ZO-1 was observed in brain
microvessels within areas of focal inﬂammatory lesions
before the onset of clinical EAE and was maintained
throughout the clinical disease course [1]. Similarly, we
previously observed a focal loss of claudin-3 immunostain-
ing from brain microvessels surrounded by inﬂammatory
cells during EAE [47]. Alterations of the molecular com-
position of BBB TJs during EAE were found to be
accompaniedbyanaberrantjunctionalmorphologydetected
at the ultrastructural level, namely pronounced TJ convolu-
tion and thereby an apparent extension of the intercellular
cleft revealing many kissing points [47].
Although the pathological alterations of BBB TJs
described above are indicative of abnormal BBB TJ func-
tion as well, observation of altered distribution or lack of
an individual TJ protein at the BBB in MS and EAE tissues
may not sufﬁce to deﬁne BBB TJ pathology or to conclude
on deﬁcient BBB TJ function in vivo. For instance,
occludin has been shown to be expressed at high levels in
brain endothelial cells [4, 22] yet the complete absence is
compatible with the development of intact BBB TJs in vivo
[38]. In contrast expression of speciﬁc occludin splice
variants (summarized in [12] or changes in phosphorylation
state may inﬂuence BBB TJ function. The latter is sup-
ported by the observation of occludin dephosphorylation in
spinal cord microvessels in a rat model of EAE corre-
sponding with the onset of CNS inﬂammation [33].
It has been suggested that during MS and EAE immune
cells migrate across the BBB via a paracellular route
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BBB leakiness and TJ pathology. This view is supported by
the observation that mice deﬁcient for the cell–cell contact
molecule PECAM-1 develop aggravated EAE due to
impaired BBB cell–cell contact integrity combined with
increased inﬂammatory cell recruitment across the BBB
into the CNS [18]. On the other hand, there is mounting
evidence that immune cell diapedesis across the BBB
during EAE might rather occur through the endothelial cell
proper, leaving BBB TJs untouched (summarized in [9]).
Therefore, alternative or more complex mechanisms of
inﬂammation-induced BBB TJ pathology must be consid-
ered. It is conceivable that in the latter scenario soluble
mediators released by immune cells might trigger BBB TJs
alterations as implied by observations showing that at least
in vitro Th17 cells can impair BBB integrity through the
combined production of IL-17A and IL-22 leading to
downregulation of occludin and to a lesser extent of ZO-1
in brain endothelial cells [23]. In addition, CD8 T cells
were shown to initiate BBB TJ disruption in vivo through a
non-apoptotic perforin-dependent mechanism [39].
In the present study, we hypothesized that experimental
sealing of BBB TJs during CNS inﬂammation would allow
us to determine the contribution of BBB TJs to immune
cell diapedesis across the BBB as compared to inﬂamma-
tion-induced BBB leakiness during EAE. Our present study
shows that TET-regulated endothelial cell-speciﬁc claudin-
1 integrated into BBB TJs and signiﬁcantly reduced BBB
leakiness for both a small molecular tracer and endogenous
plasma derived ﬁbronectin. Interestingly, although TET-
induced expression of claudin-1 could only be observed in
30–50% of brain vessels, claudin-1 induced sealing of BBB
TJs during EAE was found to signiﬁcantly ameliorate the
chronic phase of EAE in two independent transgenic
mouse lines. Our results, therefore, provide direct func-
tional evidence identifying BBB TJs as the critical
component in regulating barrier function of the BBB dur-
ing EAE and conﬁrming the notion that continued BBB TJ
alterations are the basis of BBB dysfunction, which con-
tributes to disease pathogenesis in this animal model of
MS.
At the same time, we failed to ﬁnd any difference in the
overall number or size of inﬂammatory cuffs detected in the
brains of Tie-2//TRE-claudin-1 double transgenic mice
versus their single transgenic littermates demonstrating that
claudin-1 induced sealing of BBB TJs did not inﬂuence
immune cell recruitment across the BBB during EAE.
UnimpededextravasationofimmunecellsacrosstheBBBat
sites of claudin-1 expression, therefore, implies a limited
contribution of the paracellular pathway in immune cell
diapedesis across the BBB during EAE and suggests that
transcellular immune cell trafﬁcking across the brain endo-
thelial cells proper sufﬁces to fully establish inﬂammatory
inﬁltrates in the CNS. Lack of any signiﬁcant differences
observedintheonsetandseverityoftheﬁrstclinicalepisode
of EAE between Tie-2//TRE-claudin-1 double transgenic
mice and their single transgenic littermates suggests that the
early phase of EAE pathogenesis is driven by immune cells
inﬁltrating the CNS and might explain the therapeutic efﬁ-
cacy of drugs such as natalizumab in treating MS because of
their inhibiting this process [7]. Although our study does not
allowtheelucidationofthemolecularmechanismsinitiating
inﬂammation-induced BBB leakiness in EAE, it provides
experimental in vivo evidence demonstrating that BBB
dysfunction during EAE is due to BBB TJ disruption and
identiﬁesBBBTJpathologyasaspeciﬁcpathogeneticentity
contributing to overall disease pathogenesis in EAE.
As the degree of demyelination and/or axonal damage
have been described as morphological correlates to
increasingdisabilityinMSandclinicalseverityofEAE[21],
we undertook an effort to determine if ameliorated chronic
EAE in Tie-2//TRE-claudin-1 C57BL/6 double transgenic
mice was due to reduced CNS pathology. To this end, we
performed preliminary double immunoﬂuorescence stain-
ings comparing macrophage inﬁltration and axonal injury in
correlationtodemyelinationinbrainandspinalcordsections
of Tie-2//TRE-claudin-1 C57BL/6 double transgenic mice
and single transgenic littermates during chronic EAE.
Immunostaining for F4/80 showed indistinguishable levels
of macrophage accumulation in the CNS of Tie-2//TRE-
claudin-1 C57BL/6 double transgenic mice and single
transgenic littermates. Similarly, immunostaining for MPB
andLuxolFastBluestainingrevealedcomparabledegreesof
demyelination in brain and spinal cord sections of Tie-2//
TRE-claudin-1 C57BL/6 double transgenic mice and single
transgenic littermates. Furthermore, similar degrees of
enhanced neuroﬁlament immunoﬂuorescence in spinal cord
tissue sections of Tie-2//TRE-claudin-1 C57BL/6 double
transgenic mice and single transgenic littermates were
indicative of comparable levels of axonal pathology. These
observations suggest that claudin-1 induced sealing of BBB
TJs does not readily translate into reduced CNS pathology
but might lead to an improvement of the physiological
conditions in the CNS of Tie-2//TRE-claudin-1 C57BL/6
doubletransgenicmicesustainingelectricalactivityandthus
properfunctionofCNSneurons.InducedsealingofBBBTJs
could reduce edema and radical formation, and/or improve
ion homeostasis in the CNS, and thus lead to a neuropro-
tective outcome.
Persistent endothelial abnormalities and BBB leakage
have been described in primary and secondary progressive
MS [29] indicating the existence of the same pathogenic
axis in patients. In light of the fact that progressing dis-
ability at later time points of the MS disease course is not
prevented by the current anti-inﬂammatory treatments
available [3], our present ﬁndings demonstrating a
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pathogenesis point to therapeutic sealing of BBB TJs as an
attractive alternative for the restoration of BBB function
and eventually CNS homeostasis. The challenges faced for
developing such methods are our present lack of in depth
knowledge on the precise molecular architecture of BBB
TJs as well as our incomplete understanding of the function
and regulation of expression of the individual TJ compo-
nents in BBB TJs. The recent discovery of the Wnt/b-
catenin signaling pathway involved in brain angiogenesis
and claudin-3 expression may open such a novel avenue for
therapeutic stabilization of BBB TJs during CNS
inﬂammation.
Acknowledgments Special thanks go to Dr. Silke Tauber for pre-
paring the claudin-constructs and to Therese Pe ´rinat and Claudi Blatti
for expert technical assistance. Furthermore, we wish to thank Dr.
Axinia Do ¨ring for her tireless help in the daily clinical scoring of EAE
mice,NannetteRinkformicroinjection,SorinCiocanandThomasZeis
for help with immunoﬂuorescence stainings and Svetlozar Tsonev and
Isabelle Oswald for state-of-the art mouse husbandry and care. This
work was funded by the the Swiss National Foundation, the European
Stroke Network (ESN, EU FP7 N 201024 and N 202213) and Inte-
grating Project JUSTBRAIN (EU, FP7 N HEALTH-2009-241861).
Conﬂict of interest The authors declare that they have no conﬂict
of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Bennett J, Basivireddy J, Kollar A, Biron KE, Reickmann P,
Jefferies WA, McQuaid S (2010) Blood-brain barrier disruption
and enhanced vascular permeability in the multiple sclerosis
model EAE. J Neuroimmunol 229(1–2):180–191
2. Coisne C, Dehouck L, Faveeuw C, Delplace Y, Miller F, Landry
C, Morissette C, Fenart L, Cecchelli R, Tremblay P, Dehouck B
(2005) Mouse syngenic in vitro blood-brain barrier model: a new
tool to examine inﬂammatory events in cerebral endothelium.
Lab Invest 85:734–746
3. Compston A, Coles A (2008) Multiple sclerosis. Lancet
372(9648):1502–1517
4. Daneman R, Zhou L, Agalliu D, Cahoy JD, Kaushal A, Barres
BA (2010) The mouse blood-brain barrier transcriptome: a new
resource for understanding the development and function of brain
endothelial cells. PLoS One 5(10):e13741
5. Deutsch U, Schlaeger TM, Dehouck B, Doring A, Tauber S,
Risau W, Engelhardt B (2008) Inducible endothelial cell-speciﬁc
gene expression in transgenic mouse embryos and adult mice.
Exp Cell Res 314(6):1202–1216
6. Engelhardt B (2010) T cell migration into the central nervous
system during health and disease: different molecular keys allow
access to different central nervous system compartments. Clin
Exp Neuroimmunol 1:1–15
7. Engelhardt B, Kappos L (2008) Natalizumab: targeting alpha4-
integrins in multiple sclerosis. Neurodegener Dis 5(1):16–22
8. Engelhardt B, Kempe B, Merfeld-Clauss S, Laschinger M, Furie
B, Wild MK, Vestweber D (2005) P-selectin glycoprotein ligand
1 is not required for the development of experimental autoim-
mune encephalomyelitis in SJL and C57BL/6 mice. J Immunol
175(2):1267–1275
9. Engelhardt B, Wolburg H (2004) Mini-review: transendothelial
migration of leukocytes: through the front door or around the side
of the house? Eur J Immunol 34(11):2955–2963
10. Engelhardt B, Wolburg H (2005) The blood-brain barrier in EAE.
In: ELaCS Constantinescu (ed) Experimental models of multiple
sclerosis. Springer Science ? Business Media. Inc, New York,
pp 415–449
11. Fabis MJ, Scott GS, Kean RB, Koprowski H, Hooper DC (2007)
Loss of blood-brain barrier integrity in the spinal cord is common
to experimental allergic encephalomyelitis in knockout mouse
models. Proc Natl Acad Sci USA 104(13):5656–5661
12. Feldman GJ, Mullin JM, Ryan MP (2005) Occludin: structure,
function and regulation. Adv Drug Deliv Rev 57(6):883–917
13. Fujibe M, Chiba H, Kojima T, Soma T, Wada T, Yamashita T,
Sawada N (2004) Thr203 of claudin-1, a putative phosphorylation
site for MAP kinase, is required to promote the barrier function of
tight junctions. Exp Cell Res 295(1):36–47
14. Furuse M, Hata M, Furuse K, Yoshida Y, Haratake A, Sugitani Y,
Noda T, Kubo A, Tsukita S (2002) Claudin-based tight junctions
are crucial for the mammalian epidermal barrier: a lesson from
claudin-1-deﬁcient mice. J Cell Biol 156(6):1099–1111
15. Furuse M, Sasaki H, Fujimoto K, Tsukita S (1998) A single gene
product, claudin-1 or -2, reconstitutes tight junction strands and
recruits occludin in ﬁbroblasts. J Cell Biol 143(2):391–401
16. Furuse M, Sasaki H, Tsukita S (1999) Manner of interaction of
heterogeneous claudin species within and between tight junction
strands. J Cell Biol 147(4):891–903
17. Furuse M, Tsukita S (2006) Claudins in occluding junctions of
humans and ﬂies. Trends Cell Biol 16(4):181–188
18. Graesser D, Solowiej A, Bruckner M, Osterweil E, Juedes A,
Davis S, Ruddle NH, Engelhardt B, Madri JA (2002) Altered
vascular permeability and early onset of experimental autoim-
mune encephalomyelitis in PECAM-1-deﬁcient mice. J Clin
Invest 109(3):383–392
19. Greenwood J, Heasman SJ, Alvarez JI, Prat A, Lyck R, Engel-
hardt B (2011) Leukocyte-endothelial cell crosstalk at the blood-
brain barrier: a prerequisite for successful immune cell entry to
the brain. Neuropathol Appl Neurobiol 37(1):24–39
20. Hamm S, Dehouck B, Kraus J, Wolburg-Buchholz K, Wolburg
H, Risau W, Cecchelli R, Engelhardt B, Dehouck MP (2004)
Astrocyte mediated modulation of blood-brain barrier perme-
ability does not correlate with a loss of tight junction proteins
from the cellular contacts. Cell Tissue Res 315(2):157–166
21. Herrero-Herranz E, Pardo LA, Gold R, Linker RA (2008) Pattern
of axonal injury in murine myelin oligodendrocyte glycoprotein
induced experimental autoimmune encephalomyelitis: implica-
tions for multiple sclerosis. Neurobiol Dis 30(2):162–173
22. Hirase T, Staddon JM, Saitou M, Ando-Akatsuka Y, Itoh M,
Furuse M, Fujimoto K, Tsukita S, Rubin LL (1997) Occludin as a
possible determinant of tight junction permeability in endothelial
cells. J Cell Sci 110(Pt 14):1603–1613
23. Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R,
Bernard M, Giuliani F, Arbour N, Becher B, Prat A (2007)
Human TH17 lymphocytes promote blood-brain barrier disrup-
tion and central nervous system inﬂammation. Nat Med
13(10):1173–1175
24. Kermode AG, Thompson AJ, Tofts P, MacManus DG, Kendall
BE, Kingsley DP, Moseley IF, Rudge P, McDonald WI (1990)
Breakdown of the blood-brain barrier precedes symptoms and
Acta Neuropathol (2011) 122:601–614 613
123other MRI signs of new lesions in multiple sclerosis. Pathoge-
netic and clinical implications. Brain 113(Pt 5):1477–1489
25. Kirk J, Plumb J, Mirakhur M, McQuaid S (2003) Tight junctional
abnormality in multiple sclerosis white matter affects all calibres
of vessel and is associated with blood-brain barrier leakage and
active demyelination. J Pathol 201(2):319–327. doi:10.1002/
path.1434
26. Krause G, Winkler L, Mueller SL, Haseloff RF, Piontek J, Blasig
IE (2008) Structure and function of claudins. Biochim Biophys
Acta 1778(3):631–645
27. Lassmann H (1983) Comparative neuropathology of chronic
experimental allergic encephalomyelitis and multiple sclerosis.
Springer Verlag, Berlin
28. Lassmann H, Wekerle H (2005) The pathology of multiple
sclerosis. In: Compston A (ed) Mcalpine’s multiple sclerosis.
Elsevier Chruchill Livingstone, Edinburgh, pp 557–599
29. Leech S, Kirk J, Plumb J, McQuaid S (2007) Persistent endo-
thelial abnormalities and blood-brain barrier leak in primary and
secondary progressive multiple sclerosis. Neuropathol Appl
Neurobiol 33(1):86–98
30. Liebner S, Corada M, Bangsow T, Babbage J, Taddei A, Czupalla
CJ, Reis M, Felici A, Wolburg H, Fruttiger M, Taketo MM, von
Melchner H, Plate KH, Gerhardt H, Dejana E (2008) Wnt/beta-
catenin signaling controls development of the blood-brain barrier.
J Cell Biol 183(3):409–417
31. Liebner S, Fischmann A, Rascher G, Duffner F, Grote E-H,
Kalbacher H, Wolburg H (2000) Claudin-1 and claudin-5
expression and tight junction morphology are altered in blood
vessels of human glioblastoma multiforme. Acta Neuropathol
100:323–331
32. Lyck R, Ruderisch N, Moll AG, Steiner O, Cohen CD, Engel-
hardt B, Makrides V, Verrey F (2009) Culture-induced changes in
blood-brain barrier transcriptome: implications for amino-acid
transporters in vivo. J Cereb Blood Flow Metab 29(9):1491–1502
33. Morgan L, Shah B, Rivers LE, Barden L, Groom AJ, Chung R,
Higazi D, Desmond H, Smith T, Staddon JM (2007) Inﬂamma-
tion and dephosphorylation of the tight junction protein occludin
in an experimental model of multiple sclerosis. Neuroscience
147(3):664–673
34. Morita K, Sasaki H, Furuse M, Tsukita S (1999) Endothelial
claudin: claudin-5/TMVCF constitutes tight junction strands in
endothelial cells. J Cell Biol 147(1):185–194
35. Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N, Furuse
M, Tsukita S (2003) Size-selective loosening of the blood-brain
barrier in claudin-5-deﬁcient mice. J Cell Biol 161:653–660
36. Padden M, Leech S, Craig B, Kirk J, Brankin B, McQuaid S
(2007) Differences in expression of junctional adhesion mole-
cule-A and beta-catenin in multiple sclerosis brain tissue:
increasing evidence for the role of tight junction pathology. Acta
Neuropathol 113(2):177–186
37. Plumb J, McQuaid S, Mirakhur M, Kirk J (2002) Abnormal
endothelial tight junctions in active lesions and normal-appearing
white matter in multiple sclerosis. Brain Pathol 12(2):154–169
38. Saitou M, Furuse M, Sasaki H, Schulzke JD, Fromm M, Takano
H, Noda T, Tsukita S (2000) Complex phenotype of mice lacking
occludin, a component of tight junction strands. Mol Biol Cell
11(12):4131–4142
39. Suidan GL, McDole JR, Chen Y, Pirko I, Johnson AJ (2008)
Induction of blood brain barrier tight junction protein alterations
by CD8 T cells. PLoS One 3(8):e3037
40. Tsukita S, Furuse M (2002) Claudin-based barrier in simple and
stratiﬁed cellular sheets. Curr Opin Cell Biol 14(5):531–536
41. Tsukita S, Furuse M, Itoh M (1999) Structural and signalling
molecules come together at tight junctions. Curr Opin Cell Biol
11(5):628–633
42. Uboldi C, Doring A, Alt C, Estess P, Siegelman M, Engelhardt B
(2008) L-Selectin-deﬁcient SJL and C57BL/6 mice are not
resistant to experimental autoimmune encephalomyelitis. Eur J
Immunol 38(8):2156–2167
43. Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K,
Leveque M, Tricoire-Leignel H, Nicotra A, Bourdoulous S,
TurowskiP,MaleDK,RouxF,GreenwoodJ,RomeroIA,Couraud
PO(2005)Blood-brainbarrier-speciﬁc propertiesofahumanadult
brain endothelial cell line. Faseb J 19(13):1872–1874
44. Witt KA, Mark KS, Hom S, Davis TP (2003) Effects of hypoxia-
reoxygenation on rat blood-brain barrier permeability and tight
junctional protein expression. Am J Physiol Heart Circ Physiol
285(6):H2820–H2831
45. Wolburg H, Lippoldt A (2002) Tight Junctions of the blood-brain
barrier. development, composition and regulation. Vasc Phar-
macol 28:323–337
46. Wolburg H, Neuhaus J, Kniesel U, Krauss B, Schmid EM, Ocalan
M, Farrell C, Risau W (1994) Modulation of tight junction
structure in blood-brain barrier endothelial cells. Effects of tissue
culture, second messengers and cocultured astrocytes. J Cell Sci
107(Pt 5):1347–1357
47. Wolburg H, Wolburg-Buchholz K, Kraus J, Rascher-Eggstein G,
Liebner S, Hamm S, Duffner F, Grote EH, Risau W, Engelhardt
B (2003) Localization of claudin-3 in tight junctions of the blood-
brain barrier is selectively lost during experimental autoimmune
encephalomyelitis and human glioblastoma multiforme. Acta
Neuropathol (Berl) 105(6):586–592
48. Wolburg H, Wolburg-Buchholz K, Liebner S, Engelhardt B
(2001) Claudin-1, claudin-2 and claudin-11 are present in tight
junctions of choroid plexus epithelium of the mouse. Neurosci
Lett 307(2):77–80
614 Acta Neuropathol (2011) 122:601–614
123